4-methoxy-2-(6-methoxy-2,4-dimethylphenyl)-6-methylpyrimidin-5-ol | 478036-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-methoxy-2-(6-methoxy-2,4-dimethylphenyl)-6-methylpyrimidin-5-ol
• 英文别名: 4-methoxy-2-(2-methoxy-4,6-dimethylphenyl)-6-methylpyrimidin-5-ol
• CAS: 478036-12-3
• 化学式: C₁₅H₁₈N₂O₃
• 分子量: 274.32
• InChiKey: ZHHQOZYKHQJWIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  64.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-chloro-4-methoxy-6-methyl-pyrimidin-5-ol 、 2,4-二甲基-6-甲氧基苯硼酸 在 三苯基膦钯 sodium carbonate 作用下， 以 水 、 乙酸乙酯 、 甲苯 为溶剂， 生成 4-methoxy-2-(6-methoxy-2,4-dimethylphenyl)-6-methylpyrimidin-5-ol
  参考文献：
  名称：

  2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines

  摘要：

  提供作为CRF 1受体选择性调节剂的Diarylpyrazine、diarylpyridine和diarylpyrimidine化合物。这些化合物对治疗多种中枢神经系统和外周疾病特别有效，包括压力、焦虑、抑郁、心血管疾病和进食障碍。还提供了治疗这些疾病的方法以及包装的药物组合物。Formula I的化合物也可用作CRF受体的定位探针和CRF受体结合测定中的标准。给出了使用这些化合物进行受体定位研究的方法。

  公开号：

  US20030119844A1

文献信息

• Compounds useful as reversible inhibitors of cysteine proteases
  申请人：Boehringer Ingelheim Pharmaciuticals, Inc.

  公开号：US20030232826A1

  公开（公告）日：2003-12-18

  Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds. 1

  本发明涉及一种新型的cathepsin S、K、F、L和B可逆抑制化合物，其化学式为(Ia)和(Ib)，其中R2、R3、R4、R5、R6、R7、R8、Het和X的定义如下。这些化合物可用于治疗自身免疫和其他疾病。本发明还公开了制备这种新型化合物的方法。
• 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines
  申请人：Huang Jianhua

  公开号：US20050176721A1

  公开（公告）日：2005-08-11

  Diarylpyrazine, diarylpyridine, and diarylpyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of Formula I are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

  提供了作为CRF 1 受体选择性调节剂的二芳基吡嗪、二芳基吡啶和二芳基嘧啶化合物。这些化合物在治疗许多中枢神经系统和周围疾病，特别是压力、焦虑、抑郁、心血管疾病和进食障碍方面具有用途。还提供了治疗这些疾病的方法以及包装的制药组合物。公式 I 的化合物也可用作CRF受体定位的探针，以及CRF受体结合测定中的标准。给出了使用这些化合物进行受体定位研究的方法。
• 2,5-diarypyrimidine compounds
  申请人：Huang Jianhua

  公开号：US06887875B2

  公开（公告）日：2005-05-03

  Diarylpyrimidine compounds of Formula I are provided, wherein. or a pharmaceutically acceptable salt thereof, wherein: Ar 1 and Ar 2 are independently chosen from: phenyl which is mono-, di-, or tri-substituted, 1-naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, and optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S; R is oxygen or absent; Z 2 is CR 2 ; Z 3 is nitrogen; R 1 and R 2 are independently chosen from hydrogen, halogen, amino, cyano, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted mono- or di-alkylamino, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (cycloalkyl)oxy, optionally substituted (cycloalkyl)alkoxy, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted mono- or dialkylcarboxamide; with the proviso that not all of R 1 , R 3 , and R 4 are hydrogen. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatments of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of Formula I are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

  本文提供了式I的二芳基嘧啶化合物，其中或其药学上可接受的盐，其中：Ar1和Ar2分别选择自：苯，其为单，双或三取代基，1-萘基和2-萘基，每个都可以是可选的单，双或三取代基，以及可选的单，双或三取代的杂环芳基，该杂环芳基具有1至3个环，每个环中有5至7个环成员，并且在至少一个环中，有1至约3个来自N，O和S的杂原子；R为氧或不存在；Z2为CR2；Z3为氮；R1和R2分别选择自氢，卤素，氨基，氰基，硝基，可选取代的烷基，可选取代的烯基，可选取代的炔基，可选取代的烷氧基，可选取代的单取代或双取代烷基氨基，可选取代的环烷基，可选取代的（环烷基）烷基，可选取代的（环烷基）氧基，可选取代的（环烷基）烷氧基，可选取代的烷硫基，可选取代的烷基亚砜基，可选取代的烷基磺酰基和可选取代的单取代或双取代烷基羧酰胺；但R1，R3和R4并非全部为氢。这些化合物在治疗多种中枢神经系统和外周疾病中有用，特别是压力，焦虑，抑郁，心血管疾病和饮食失调。本文还提供了治疗这些疾病的方法以及包装的制药组合物。式I的化合物也可用作CRF受体定位的探针以及CRF受体结合测定中的标准。给出了使用这些化合物进行受体定位研究的方法。
• 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS
  申请人：Neurogen Corporation

  公开号：EP1399428A1

  公开（公告）日：2004-03-24
• US6858623B2
  申请人：——

  公开号：US6858623B2

  公开（公告）日：2005-02-22